Paul Glue1, Shona M Neehoff1, Natalie J Medlicott2, Andrew Gray3, Guy Kibby4, Neil McNaughton5. 1. 1 Department of Psychological Medicine, University of Otago, Dunedin, New Zealand. 2. 2 School of Pharmacy, University of Otago, Dunedin, New Zealand. 3. 3 Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand. 4. 4 Southern District Health Board, Dunedin, New Zealand. 5. 5 Department of Psychology, University of Otago, Dunedin, New Zealand.
Abstract
OBJECTIVE: In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment. METHODS: This was an uncontrolled open-label study in 20 patients who had been responders in an ascending dose ketamine study. The study was undertaken in a university clinic. Patients received one or two weekly ketamine doses of 1 mg/kg injected subcutaneously for 3 months. Data were collected from December 2015-June 2017. RESULTS: There were 10 women (50%) and 10 men (50%); 15 patients (75%) met criteria for GAD and 18 (90%) for SAD. One hour after dosing, Fear Questionnaire ratings decreased by ~50%, as did Hamilton Anxiety ratings. Clinician Administered Dissociative States Scale mean scores declined over time, from 20 points at week 1 to 8.8 points at week 14. Compared with pre-dose values, mean systolic and diastolic blood pressure increased by ~10 mm Hg at 30 min. The most common adverse events were nausea, dizziness and blurred vision. Of the 20 patients, 18 reported improved social functioning and/or work functioning during maintenance treatment. CONCLUSIONS: Weekly ketamine dosing was safe and well tolerated, and post-dose dissociative symptoms tended to reduce after repeated dosing. Patients reported marked improvements in functionality and in their personal lives. Maintenance ketamine may be a therapeutic alternative for patients with treatment refractory GAD/SAD. TRIAL REGISTRATION: http://www.anzctr.org.au/ACTRN12615000617561.
OBJECTIVE: In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment. METHODS: This was an uncontrolled open-label study in 20 patients who had been responders in an ascending dose ketamine study. The study was undertaken in a university clinic. Patients received one or two weekly ketamine doses of 1 mg/kg injected subcutaneously for 3 months. Data were collected from December 2015-June 2017. RESULTS: There were 10 women (50%) and 10 men (50%); 15 patients (75%) met criteria for GAD and 18 (90%) for SAD. One hour after dosing, Fear Questionnaire ratings decreased by ~50%, as did Hamilton Anxiety ratings. Clinician Administered Dissociative States Scale mean scores declined over time, from 20 points at week 1 to 8.8 points at week 14. Compared with pre-dose values, mean systolic and diastolic blood pressure increased by ~10 mm Hg at 30 min. The most common adverse events were nausea, dizziness and blurred vision. Of the 20 patients, 18 reported improved social functioning and/or work functioning during maintenance treatment. CONCLUSIONS: Weekly ketamine dosing was safe and well tolerated, and post-dose dissociative symptoms tended to reduce after repeated dosing. Patients reported marked improvements in functionality and in their personal lives. Maintenance ketamine may be a therapeutic alternative for patients with treatment refractory GAD/SAD. TRIAL REGISTRATION: http://www.anzctr.org.au/ACTRN12615000617561.
Entities:
Keywords:
Ketamine; generalised anxiety disorder; maintenance treatment; social anxiety disorder
Authors: Elizabeth T Brandley; Anna E Kirkland; Michael Baron; James N Baraniuk; Kathleen F Holton Journal: Front Psychiatry Date: 2022-06-20 Impact factor: 5.435
Authors: Michael D Kritzer; Nicholas A Mischel; Jonathan R Young; Christopher S Lai; Prakash S Masand; Steven T Szabo; Sanjay J Mathew Journal: Ann Clin Psychiatry Date: 2022-02 Impact factor: 2.691
Authors: Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom Journal: Depress Anxiety Date: 2019-06-23 Impact factor: 6.505
Authors: Madeeha Nasir; Daniel Trujillo; Jessica Levine; Jennifer B Dwyer; Zachary W Rupp; Michael H Bloch Journal: Front Psychiatry Date: 2020-11-19 Impact factor: 4.157
Authors: Sanne Y Smith-Apeldoorn; Jolien K E Veraart; Jeanine Kamphuis; Antoinette D I van Asselt; Daan J Touw; Marije Aan Het Rot; Robert A Schoevers Journal: BMC Psychiatry Date: 2019-11-29 Impact factor: 3.630
Authors: Eduard Falk; Daniel Schlieper; Patrick van Caster; Matthias J Lutterbeck; Jacqueline Schwartz; Joachim Cordes; Ina Grau; Peter Kienbaum; Martin Neukirchen Journal: BMC Palliat Care Date: 2020-01-03 Impact factor: 3.234